CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...